Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study.
A new therapeutic combination to combat resistant sarcomas has shown promise in a trial.
An experimental immunotherapy agent was placed on the US Food and Drug Administration's fast track to market approval after overwhelmingly positive results were seen in patients with leukemia. In early trials, 89% of patients who received the personalized immunotherapy known as CTL019 saw their cancers disappear.
Surgical biopsy is safe for certain late-stage lung cancer patients and could improve their chances of getting treated with newer types of drugs that target cancer-related genetic mutations.
Results of a phase I clinical trial of a vaccine therapy for pancreatic cancer indicate the treatment is well tolerated; in addition, it suggests that the vaccine stabilizes the disease for a period of time.
A study using a 5-year LDCT screening protocol showed good adherence and patient survival outcomes in persons at high risk of developing lung cancer.
An increasingly complex environment for cancer care and research highlights the need to streamline access to cancer information, especially clinical trials.
Clinical trials have begun for PFK-158, a small-molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.
Expanding the National Cancer Institute (NCI) Community Cancer Centers Program within a rural community can increase the number of patients enrolled in clinical trials
Fewer than 5% of adults with cancer enroll in clinical trials, despite such enrollment being critical to evaluate new therapies.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody.
Created by the Society for Immunotherapy of Cancer (SITC), this video follows a sample patient's journey from the diagnosis of NSCLC through the process of learning about cancer immunology.
A practical risk-management approach for effectively integrating biomarkers into cancer clinical trials has been outlined by a working group.
Clinical trials for a new experimental drug, CPX-351, to treat acute myeloid leukemia are very promising, according to researchers.
Approximately half of all patients with a diagnosis of non-small cell lung cancer are age 70 years or older, yet elderly patients are not well represented in clinical trials.
ANAHEIM, CALIFORNIA—Intervention fidelity is an essential element of randomized, clinical trials. To illustrate this point, one researcher described how intervention fidelity was incorporated into her clinical trial evaluating self-administration of acupressure for persistent cancer-related fatigue in breast cancer.
Among patients with non-small cell lung cancer treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes.
Patients with recurrent or metastatic squamous cell carcinoma of the head and neck may benefit from treatment with the investigational drug dacomitinib.
AG-221, a novel inhibitor of isocitrate dehydrogenase 2-mutant metabolic enzyme, showed early promise in patients with advanced and refractory blood cancers harboring IDH2 mutations.
The new oral drug LY2835219, an inhibitor of cyclin-dependent kinases 4 and 6, showed early promise as monotherapy for patients with metastatic breast cancer.
The investigational drug DEDN6525A, a new antibody-drug conjugate, was safe, tolerable, and showed hints of activity against three forms of melanoma: cutaneous, mucosal, and ocular.
The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for HR-negative, HER2-positive primary (nonmetastatic) breast cancer patients.
A new type of immunotherapy that directs patients' immune responses toward tumor cell killing, IMCgp100, showed efficacy in some patients with advanced melanoma.
Patients with a variety of hematologic cancers benefited from treatment with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain proteins.
Although the cumulative success rate for new agents for advanced NSCLC is lower than the industry-estimated rate, clinical trial success has been substantially increased by biomarker- and receptor-targeted therapies.
Health-related quality of life assessment in randomized clinical trials in small cell lung cancer provides added information in studies where the treatment arms do not differ in terms of efficacy.
The diabetes drug metformin is undergoing investigation as a potential treatment for different cancers in numerous clinical trials, but results vary.
A phase 1 trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe and provides early evidence for antitumor activity.
The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.
Imetelstat, a novel telomerase-inhibiting drug, has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis, according to a new study. The results were presented at the 2013 ASH Annual Meeting, in New Orleans.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|